中国医药导刊
中國醫藥導刊
중국의약도간
Chinese Journal of Medical Guide
2015年
9期
939-940,942
,共3页
二甲双胍%代谢综合征%高胰岛素-正常血糖钳夹试验%葡萄糖代谢率%脂肪因子
二甲雙胍%代謝綜閤徵%高胰島素-正常血糖鉗夾試驗%葡萄糖代謝率%脂肪因子
이갑쌍고%대사종합정%고이도소-정상혈당겸협시험%포도당대사솔%지방인자
Metformin%Metabolic syndrome%Hyperinsulinemic euglycemic clamp%Glucose metabolic rate%Fat factor
目的:研究二甲双胍治疗对代谢综合征(MS)患者葡萄糖代谢率及脂肪水平的影响.方法:选取2013年5月至2014年5月在我院接受治疗的代谢综合征患者45例(观察组)和健康对照者45例(对照组),观察组给予盐酸二甲双胍治疗,治疗前后测定相应指标.结果:MS患者的体重指数(BMI)、空腹血糖(FPG)、空腹胰岛素(FINS)、血浆甘油三酯等均显著高于对照组(P<0.05),高密度脂蛋白(HDL-C)水平显著低于对照组(P<0.05),胰岛素-正常血糖钳夹试验结果显示,观察组的葡萄糖代谢率显著低于对照组(P<0.05).观察组接受治疗后,体重指数(BMI)、空腹血糖(FPG)、空腹胰岛素(FINS)、血浆甘油三酯等生化指标水平较治疗前显著降低(P<0.05).治疗前后观察组的葡萄糖代谢率分别为(4.56±1.45)和(6.33±1.67),P<0.05.观察组治疗前后脂连素水平无显著差异(P>0.05),而血浆瘦素水平治疗后与治疗前比显著降低(P<0.05).结论:MS患者经过二甲双胍治疗后,血糖、血脂等生化指标得到显著改善,二甲双胍能够降低血浆瘦素水平,改善胰岛素抵抗.
目的:研究二甲雙胍治療對代謝綜閤徵(MS)患者葡萄糖代謝率及脂肪水平的影響.方法:選取2013年5月至2014年5月在我院接受治療的代謝綜閤徵患者45例(觀察組)和健康對照者45例(對照組),觀察組給予鹽痠二甲雙胍治療,治療前後測定相應指標.結果:MS患者的體重指數(BMI)、空腹血糖(FPG)、空腹胰島素(FINS)、血漿甘油三酯等均顯著高于對照組(P<0.05),高密度脂蛋白(HDL-C)水平顯著低于對照組(P<0.05),胰島素-正常血糖鉗夾試驗結果顯示,觀察組的葡萄糖代謝率顯著低于對照組(P<0.05).觀察組接受治療後,體重指數(BMI)、空腹血糖(FPG)、空腹胰島素(FINS)、血漿甘油三酯等生化指標水平較治療前顯著降低(P<0.05).治療前後觀察組的葡萄糖代謝率分彆為(4.56±1.45)和(6.33±1.67),P<0.05.觀察組治療前後脂連素水平無顯著差異(P>0.05),而血漿瘦素水平治療後與治療前比顯著降低(P<0.05).結論:MS患者經過二甲雙胍治療後,血糖、血脂等生化指標得到顯著改善,二甲雙胍能夠降低血漿瘦素水平,改善胰島素牴抗.
목적:연구이갑쌍고치료대대사종합정(MS)환자포도당대사솔급지방수평적영향.방법:선취2013년5월지2014년5월재아원접수치료적대사종합정환자45례(관찰조)화건강대조자45례(대조조),관찰조급여염산이갑쌍고치료,치료전후측정상응지표.결과:MS환자적체중지수(BMI)、공복혈당(FPG)、공복이도소(FINS)、혈장감유삼지등균현저고우대조조(P<0.05),고밀도지단백(HDL-C)수평현저저우대조조(P<0.05),이도소-정상혈당겸협시험결과현시,관찰조적포도당대사솔현저저우대조조(P<0.05).관찰조접수치료후,체중지수(BMI)、공복혈당(FPG)、공복이도소(FINS)、혈장감유삼지등생화지표수평교치료전현저강저(P<0.05).치료전후관찰조적포도당대사솔분별위(4.56±1.45)화(6.33±1.67),P<0.05.관찰조치료전후지련소수평무현저차이(P>0.05),이혈장수소수평치료후여치료전비현저강저(P<0.05).결론:MS환자경과이갑쌍고치료후,혈당、혈지등생화지표득도현저개선,이갑쌍고능구강저혈장수소수평,개선이도소저항.
Objective: To investigate the effects of metformin on glucose metabolic rate (M) and fat levels in patients with metabolic syndrome(MS).Methods:From May 2013 to May 2014 in our hospital for treatment of patients with metabolic syndrome (observation group) and 45 healthy controls (control group), the observation group was treated with metformin hydrochloride, and the corresponding indexes were measured before and after treatment.Results:MS patients with body mass index (BMI), fasting plasma glucose (FPG),fasting insulin (fins),plasma triglyceride were significantly higher than those of the control group (P<0.05), high density lipoprotein cholesterol (HDL-C) level was significantly lower than that of control group (P<0.05),hyperinsulinemic euglycemic clamp test results show that the observation group of glucose metabolism rate was significantly lower than that of the control group (P<0.05). After treatment, body mass index (BMI),fasting blood glucose (FPG), fasting insulin (FINS),plasma triglyceride and other biochemical indicators were significantly lower than before treatment (P<0.05). The glucose metabolic rate in the observation group was (4.56±1.45) and (6.33±1.67),P<0.05.There was no significant difference in the levels of adiponectin (P>0.05) in the observation group,while the plasma leptin level was significantly lower than that in the treatment group (P<0.05).Conclusion:After metformin treatment,MS patients with blood glucose,blood lipids and other biochemical indicators have been significantly improved, metformin can reduce plasma leptin levels, improve insulin resistance.
